Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule
Related Experiment Video
Updated: Oct 23, 2026

Working with Human Tissues for Translational Cancer Research
Published on: November 26, 2015
Abstract:
The Food and Drug Administration (FDA) is amending its investigational new drug application (IND) regulations to clarify that, within 30 days after the receipt of an IND for any clinical investigation involving an exception from informed consent, FDA will provide a written determination as to whether the investigation may begin. This action is intended to clarify a recent amendment to the IND regulations for clinical investigations involving an exception from informed consent that states that FDA will provide a written authorization within 30 days of receipt of the IND.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Drug Regulation
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioavailability Study Design: Healthy Subjects Versus Patients
Preclinical Development: Overview